Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
IPO Year: 2020
Exchange: NASDAQ
Website: kiromic.com
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
10-Q - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
10-Q - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from follow-up visits for Patient 4 and Patient 6 in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. At the six-month follow-up visit, Patient 4 maintained stable disease with a 5.3% reduction in tumor size compared to the pre-treatment size. At the two-month follow-up visit, Patient 6 demonstrated stable disease with no new lesions detected and no si
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports good safety and favorable ongoing efficacy results from the 10-month follow-up visit of the first patient treated in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. In this patient, the tumor size was reduced by approximately 27% compared with the pre-treatment size, and no new sites of disease were identified. As a result, the progression-free survival (PFS) has reached 10 months with
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. The UACC is one of the 57 NCI-Designated Comprehensive Cancer Centers in the U.S. Dr. Ricklie Ann Julian, Assistant Professor of Medicine at UACC, will serve as Principal Investigator at the site. "We are delighted to partner with UACC, expanding our Deltace
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announced today that the Deltacel-01 Safety Monitoring Committee (SMC) has unanimously voted in favor of proceeding with the expansion phase of the Deltacel-01 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. This recommendation by the SMC follows a favorable review of safety data from the first two cohorts, including recent results from the 40-day follow-up visit of the sixth patient in Deltacel-01, which demonstrate
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy. The designation was awarded for KB-GDT-01 in combination with low-dose radiation therapy for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on at least two lines of standard of care therapy including platinum-based chemotherapy, immune checkpoint inhibitors and targeted therapy to improve progression-free survival and overall survival. Deltacel is currently being evaluated in the Delta
On track to initiate Part 2 in September Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. Based on data from the five patients evaluated for Progression-Free Survival (PFS) in the long-term follow-up, Kiromic has registered a PFS ranging from 2 to 8 months, with an average of 4.8 months. No dose limiting toxicities (DLTs) have been r
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company"), reports favorable eight-month follow-up results from the first patient enrolled in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. Scans taken eight months post-treatment showed the patient's tumor size had decreased by 20% compared with the pre-treatment size and no new tumor lesions were detected, which indicate an eight-month progression-free survival. This follows a 13% reduction detecte
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial's Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces plans to advance the Deltacel-01 Phase 1 clinical trial to the Expansion Phase following a positive assessment from the Deltacel-01 Safety Monitoring Committee (SMC). The SMC convened on July 16th and reviewed safety and efficacy data collected to-date in Deltacel-01, confirming favorable results and optimal dose. The Deltacel-01 trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial's Second Cohort Expected in July Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports follow-up results from the second, third and fourth patients enrolled in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. The third and fourth patient
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. Scans taken six months post-treatment showed the patient's tumor size had decreased by 13% compared with the pre-treatment size, and no new tumor lesions were detected, which tran
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13D - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13D/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13D - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13G - Kiromic Biopharma, Inc. (0001792581) (Subject)
Recent Corporate Highlights Include: New Leadership Appointed at the Company, Board of Director Level Completed Studies to Further Optimize Potency and Validity of the ALEXIS Gamma Delta T (GDT) Cell Platform Progressed a Master Cell Bank Strategy for Retro-viral Vector (RVV) Production Enhanced Kiromic's Diamond AI™ Mediated Pooled Donor Gamma Delta T Cell Banking Technology Expansion and Redesign of In-house cGMP Manufacturing Facility DIAMOND®AI 2.0 New Component NOEMI (NeurO Evolutive) Machine Learning Enabled Antibody Design) Designed to Dramatically Reduce Time and Cost of CAR-T Cell Therapy Development Cash Position $15,123,100 as of March 31, 2022 Kiromic BioPh
Highlights Include Company's Progress in the Following Areas: Advances in the Research, Development, and Manufacturing Processes of the ALEXIS Gamma Delta T cell Platform Key Hires in Research & Development, Clinical Translational Medicine and Clinical Trial Preparation Completion of Approximately 90% of In-house cGMP Facility Expansion and Redesign Launch of DIAMOND® Artificial Intelligence (AI) 2.0 Platform for Identification and Selection of Immunotherapy Targets, which Now Includes Nearly Two Billion Data Points Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artific
Kiromic Biopharma, Inc. (NASDAQ:KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005822/en/http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview (Graphic: Business Wire)">SpliceSeq, http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview (Graphic: Business Wire) InSilico Solutions is a world-class bio-informatics and artificial intelligence innovator with a long standing collaborative relationship with its clients at MD Anderson Cancer Center, Johns Hopkins School of
Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company's Vice President of Research & Development and Clinical Translation since September 2021. His previous role was Head of Clinical Translation from 2020 to 2021, having joined the Company in 2016 as Executive Director of Research and Development (R&D). "We are delighted to name
– Frank Tirelli Will Serve as Chair of Kiromic's Audit Committee – – Dr. Reeves Brings Deep Biopharmaceutical, Regulatory, and Clinical Expertise to Board Role – Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces the appointment of two outside directors to the Company's Board of Directors: Frank Tirelli and Karen Reeves, M.D. Frank Tirelli was appointed to the Company's Board effective on January 28,
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP) — Expansion of in-house cGMP manufacturing facility to provide support to the Company's clinical trials. Therapeutic doses expected to be ready for first in-human dosing in 3Q-2021. — Mr. Ignacio Núñez, a 20-year industry veteran in global operations and manufacturing, is joining the Kiromic team to take the company to the next level and to scale up cGMP manufacturing capabilities internally. Kiromic is an immuno-oncology company using Artificial Intelligence (AI) to identify critical markers in solid tumors to develop Allogeneic CAR-T cell therapy. Kiromic’s CAR-T technology addresses critical efficacy and safet
Gainers Infinity Pharmaceuticals (NASDAQ:INFI) shares increased by 23.7% to $0.04 during Wednesday's after-market session. Trading volume for this security closed at 3.2 million, accounting for 94.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.9 million. TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 15.55% to $1.04. The company's market cap stands at $2.1 million. Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares increased by 14.94% to $0.01. Scinai Immunotherapeutics (NASDAQ:SCNI) shares increased by 11.45% to $1.46. Today's trading volume for this security ended up closing at 582.8K shares, which i
Monday's session saw 175 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Pfizer (NYSE:PFE). The smallest company by market cap to set a new 52-week low was Kiromic BioPharma (NASDAQ:KRBP). Tenon Medical (NASDAQ:TNON) made the largest move down on the session, with shares plummeting 38.98% to reach its 52-week low. Revance Therapeutics (NASDAQ:RVNC) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Stocks that set new 52-week lows on Monday are as follows: Pfizer (NYSE:PFE) shares moved down 1.71% on Monday to hit a new 52-week low of $33.54, drif
On Thursday, 283 companies set new 52-week lows. 52-Week Low Highlights: The largest company by market cap to set a new 52-week low was Pfizer (NYSE:PFE). Blue Star Foods (NASDAQ:BSFC) was the smallest company when considering market cap to set a new 52-week low. Edible Garden AG (NASDAQ:EDBL) made the largest move down on the session, with shares plummeting 34.15% to reach its 52-week low. Almacenes Exito (NYSE:EXTO) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. The following stocks created new 52-week lows on Thursday: Pfizer (NYSE:PFE) shares made a new 52-week low of $34.04 on Thursday. The stock was down 0.74% for the day. Walt Disney
On Tuesday morning, 164 companies achieved new lows for the year. 52-Week Low Highlights: NextEra Energy (NYSE:NEE) was the largest firm by market cap to set a new 52-week low. SenesTech (NASDAQ:SNES) was the smallest company in terms of market cap to set a new 52-week low. WeWork (NYSE:WE) saw the largest move of the companies, as shares plummetted 3189.55% to hit a new 52-week low. Tarena International (NASDAQ:TEDU)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low. Here is a list of stocks that set new 52-week lows on Tuesday: NextEra Energy (NYSE:NEE) stock dropped to a yearly low on Tuesday of $65.95. Shares traded down 1.0
On Tuesday, 210 companies reached new 52-week lows. Interesting Points From Today's 52-Week Lows: Enbridge (NYSE:ENB) was the largest firm by market cap to set a new 52-week low. First Wave BioPharma (NASDAQ:FWBI) was the smallest company in terms of market cap to set a new 52-week low. Republic First Bancorp (NASDAQ:FRBK)'s stock came under the most pressure, trading down 37.14% to reach a new 52-week low. Monro (NASDAQ:MNRO)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low. The stocks that set new 52-week lows on Tuesday: Enbridge (NYSE:ENB) stock set a new 52-week low of $34.46 on Tuesday, moving down 0.63%. Target (NYSE:TGT) stock hit
On Tuesday, 46 stocks hit new 52-week lows. Key Facts About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Moderna (NASDAQ:MRNA). American Rebel Holdings (NASDAQ:AREB) was the smallest firm by market cap to set a new 52-week low. Polished.com (AMEX:POL) made the largest move down on the session, with shares plummeting 66.66% to reach its 52-week low. Brera Holdings (NASDAQ:BREA)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low. Here is a list of stocks that set new 52-week lows on Tuesday: Moderna (NASDAQ:MRNA) stock hit $114.40 on Tuesday morning, setting a new 52-week low for a change of
Friday's session saw 59 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Bristol-Myers Squibb (NYSE:BMY) was the largest firm by market cap to set a new 52-week low. BitNile Metaverse (NASDAQ:BNMV) was the smallest company in terms of market cap to set a new 52-week low. Tonix Pharmaceuticals (NASDAQ:TNXP) saw the largest move of the companies, as shares plummetted 38.2% to hit a new 52-week low. ClearPoint Neuro (NASDAQ:CLPT)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low. The following stocks created new 52-week lows on Friday: Bristol-Myers Squibb (NYSE:BMY) shares were up 0.07% for the day, having made a
Gainers Addentax Group Corp. (NASDAQ:ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) surged 40% to $10.97. Cyteir Therapeutics, Inc. (NASDAQ:CYT) shares gained 38% to $2.6487. Cyteir Therapeutics reported discontinuation of CYT-0851 development program and planned liquidation and dissolution. TOP Financial Group Limited (NASDAQ:TOP) shares gained 32.2% to $10.31 after the company reported FY23 financial results. Renalytix Plc (NASDAQ:RNLX) shares jumped 31% to $2.66 after the company received FDA De Novo marketing autho
Gainers Renalytix (NASDAQ:RNLX) shares moved upwards by 38.6% to $2.87 during Friday's pre-market session. The company's market cap stands at $134.5 million. Cyteir Therapeutics (NASDAQ:CYT) stock rose 28.12% to $2.46. The market value of their outstanding shares is at $87.3 million. CymaBay Therapeutics (NASDAQ:CBAY) stock increased by 22.7% to $9.62. The company's market cap stands at $938.0 million. CytomX Therapeutics (NASDAQ:CTMX) stock rose 21.98% to $1.72. The company's market cap stands at $114.1 million. Baudax Bio (NASDAQ:BXRX) stock increased by 21.14% to $0.63. The market value of their outstanding shares is at $3.8 million. Alvotech (NASDAQ:ALVO) stock rose 11.59% to $7.7.
Gainers Renalytix Plc (NASDAQ:RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. Genfit S.A. (NASDAQ:GNFT) shares gained 26.6% to $5.24 in pre-market trading. Ipsen and GENFIT disclosed positive results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease. Lion Group Holding Ltd. (NASDAQ:LGHL) shares rose 27.2% to $0.1222 in pre-market trading. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares rose 15.2% to $10.55 in pre-market trading after the board announced exploration of strategic alternatives to maxi